Purpose: This first-in-human study assessed safety, tolerability, pharmacokinetics,
pharmacodynamics, and preliminary clinical activity of single and multiple doses of TAK …

Purpose This study describes the antiproliferative activity of the multikinase inhibitor R1530
in vitro and its antitumor and anti-angiogenic activity, pharmacokinetics, and tolerability in …

Purpose: The purpose of this research was to assess in vivo by dynamic contrast enhanced
magnetic resonance imaging (DCE-MRI) the antiangiogenic effect of SU6668, an oral, small …

3516 Background: Aberrant Hh signaling pathway activation has been implicated in a
variety of cancers via both Hh ligand-independent and ligand-dependent overexpression …

Objective Our objective was to assess the pharmacokinetics of erlotinib in a large patient
population with solid tumors, identify covariates, and explore relationships between …

With the development of targeted therapeutics, especially for small-molecule inhibitors, it is
important to understand whether the observed in vivo efficacy correlates with the modulation …

PURPOSE: Despite improvements in chemoradiation, local control remains a major clinical
problem in locally advanced non-small cell lung cancer. The Hedgehog pathway has been …

Background ZD6126 is a novel vascular-targeting agent that disrupts the endothelial tubulin
cytoskeleton causing selective occlusion of tumor vasculature and extensive tumor necrosis …

The angiogenic phenotype is associated with increased tumor neovascularization and a
state of vascular hyperpermeability to macromolecules. Angiogenesis inhibitors could …

Effective delivery of chemotherapeutic agents to tumors is a critical objective of improved
cancer therapy. Traditional antiangiogenic therapy aims at eradicating tumor blood vessels …